Search research articles
Contact Us
Filters
Showing results (91-100 of 127) with videos related to
Page
of 13
Sort By:
Journal of Immunotherapy with Emphasis on Tumor Immunology : Official Journal of the Society for Biological Therapy
|
March 1, 1996
Endocrine effects of IL-1 alpha and beta administered in a phase I trial to patients with advanced cancer
B D Curti, W J Urba, D L Longo, et al.
Blood
|
March 27, 2001
A prospective randomized phase II trial of GM-CSF priming to prevent topotecan-induced neutropenia in chemotherapy-naive patients with malignant melanoma or renal cell carcinoma
J E Janik, L L Miller, E L Korn, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 31, 2023
SALVO: Single-Arm Trial of Ipilimumab and Nivolumab as Adjuvant Therapy for Resected Mucosal Melanoma
Lisa A Kottschade, Gregory Russell Pond, Anthony J Olszanski, et al.
Clinical Immunology (Orlando, Fla.)
|
December 22, 1999
Treatment with tumor necrosis factor-alpha and granulocyte-macrophage colony-stimulating factor increases epidermal Langerhans' cell numbers in cancer patients
J E Janik, L L Miller, W C Kopp, et al.
Cancer Journal (Sudbury, Mass.)
|
July 6, 2000
Combination chemotherapy followed by an immunotoxin (anti-B4-blocked ricin) in patients with indolent lymphoma: results of a phase II study
D L Longo, P L Duffey, J G Gribben, et al.
Nature Communications
|
February 17, 2021
Neoadjuvant anti-OX40 (MEDI6469) therapy in patients with head and neck squamous cell carcinoma activates and expands antigen-specific tumor-infiltrating T cells
Rebekka Duhen, Carmen Ballesteros-Merino, Alexandra K Frye, et al.
Blood
|
May 11, 1999
Abrogation of the hematological and biological activities of the interleukin-3/granulocyte-macrophage colony-stimulating factor fusion protein PIXY321 by neutralizing anti-PIXY321 antibodies in cancer patients receiving high-dose carboplatin
L L Miller, E L Korn, D S Stevens, et al.
JAMA
|
June 8, 2006
Sunitinib in patients with metastatic renal cell carcinoma
Robert J Motzer, Brian I Rini, Ronald M Bukowski, et al.
Cancer Discovery
|
April 17, 2019
A First-in-Human Study and Biomarker Analysis of NKTR-214, a Novel IL2Rβγ-Biased Cytokine, in Patients with Advanced or Metastatic Solid Tumors
Salah-Eddine Bentebibel, Michael E Hurwitz, Chantale Bernatchez, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 15, 1998
Phase I trial of anti-CD3-stimulated CD4+ T cells, infusional interleukin-2, and cyclophosphamide in patients with advanced cancer
B D Curti, A C Ochoa, G C Powers, et al.
Page
of 13
Search research articles
Search
Showing results (91-100 of 127) with videos related to
Sort By:
Page
of 13
Journal of Immunotherapy with Emphasis on Tumor Immunology : Official Journal of the Society for Biological Therapy
|
March 1, 1996
Endocrine effects of IL-1 alpha and beta administered in a phase I trial to patients with advanced cancer
B D Curti, W J Urba, D L Longo, et al.
Blood
|
March 27, 2001
A prospective randomized phase II trial of GM-CSF priming to prevent topotecan-induced neutropenia in chemotherapy-naive patients with malignant melanoma or renal cell carcinoma
J E Janik, L L Miller, E L Korn, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 31, 2023
SALVO: Single-Arm Trial of Ipilimumab and Nivolumab as Adjuvant Therapy for Resected Mucosal Melanoma
Lisa A Kottschade, Gregory Russell Pond, Anthony J Olszanski, et al.
Clinical Immunology (Orlando, Fla.)
|
December 22, 1999
Treatment with tumor necrosis factor-alpha and granulocyte-macrophage colony-stimulating factor increases epidermal Langerhans' cell numbers in cancer patients
J E Janik, L L Miller, W C Kopp, et al.
Cancer Journal (Sudbury, Mass.)
|
July 6, 2000
Combination chemotherapy followed by an immunotoxin (anti-B4-blocked ricin) in patients with indolent lymphoma: results of a phase II study
D L Longo, P L Duffey, J G Gribben, et al.
Nature Communications
|
February 17, 2021
Neoadjuvant anti-OX40 (MEDI6469) therapy in patients with head and neck squamous cell carcinoma activates and expands antigen-specific tumor-infiltrating T cells
Rebekka Duhen, Carmen Ballesteros-Merino, Alexandra K Frye, et al.
Blood
|
May 11, 1999
Abrogation of the hematological and biological activities of the interleukin-3/granulocyte-macrophage colony-stimulating factor fusion protein PIXY321 by neutralizing anti-PIXY321 antibodies in cancer patients receiving high-dose carboplatin
L L Miller, E L Korn, D S Stevens, et al.
JAMA
|
June 8, 2006
Sunitinib in patients with metastatic renal cell carcinoma
Robert J Motzer, Brian I Rini, Ronald M Bukowski, et al.
Cancer Discovery
|
April 17, 2019
A First-in-Human Study and Biomarker Analysis of NKTR-214, a Novel IL2Rβγ-Biased Cytokine, in Patients with Advanced or Metastatic Solid Tumors
Salah-Eddine Bentebibel, Michael E Hurwitz, Chantale Bernatchez, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 15, 1998
Phase I trial of anti-CD3-stimulated CD4+ T cells, infusional interleukin-2, and cyclophosphamide in patients with advanced cancer
B D Curti, A C Ochoa, G C Powers, et al.
Page
of 13